VVP
TAK icon

Venture Visionary Partners’s Takeda Pharmaceutical TAK Stock Holding History

Venture Visionary Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-206
Closed -$2.89K – 1418
2022
Q2 		$2.89K Buy
+206
New +$2.94K ﹤0.01% 1494

Other funds holding TAK

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Venture Visionary Partners's TAK Position: Q3 2022 in Review

Venture Visionary Partners sold out of Takeda Pharmaceutical (TAK) in Q3 2022, closing a stake of 206 shares — an estimated $2.89K sold.

Venture Visionary Partners first reported a position in TAK in Q2 2022 and held it in 1 quarter. The position peaked at $2.89K in Q2 2022. 276 funds tracked by Wall St. Rank hold TAK as of Q3 2022.

  • Venture Visionary Partners reported no remaining Takeda Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 206 Takeda Pharmaceutical shares in Q3 2022, an estimated $2.89K.
  • Venture Visionary Partners first reported a position in Takeda Pharmaceutical in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Takeda Pharmaceutical position peaked at $2.89K in Q2 2022.
  • 276 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.